Article thumbnail

Targeted expression of tumor necrosis factor-related apoptosis-inducing ligand TRAIL in skin protects mice against chemical carcinogenesis

By Valerie Kedinger, Stephanie Muller and Hinrich Gronemeyer
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3078898
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2005). A: Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
  2. (1984). Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature
  3. (2007). AE: Mouse skin chemical carcinogenesis is inhibited by antizyme in promotion-sensitive and promotion-resistant genetic backgrounds. Mol Carcinog
  4. (1995). al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity
  5. (1999). al: Safety and antitumor activity of recombinant soluble Apo2 ligand.
  6. (1999). Alnemri ES, El-Deiry WS: Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res
  7. (1997). Alnemri ES: Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL.
  8. (2010). Ashkenazi A: New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene
  9. (1986). Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature
  10. (2000). Chambon P: Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis. Nature
  11. (2010). Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature
  12. (2007). Chiao PJ, et al: Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAILinduced death. Cancer Cell
  13. (2010). Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells? Cell Mol Life Sci
  14. (2011). Critical role for tumor necrosis factor-related apoptosisKedinger et al. Molecular Cancer
  15. (2005). Cutting edge: TRAIL deficiency accelerates hematological malignancies.
  16. (1989). E: Tissue-specific and differentiation-specific expression of a human K14 keratin gene in transgenic mice.
  17. (2004). ElDeiry WS: Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol
  18. (2005). et al: Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res
  19. (2005). et al: HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo.
  20. (2003). et al: Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosisinducing ligand (TRAIL).
  21. (1997). et al: TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. Embo J
  22. (1999). et al: Tumoricidal activity of tumor necrosis factorrelated apoptosis-inducing ligand in vivo. Nat Med
  23. (2003). G: TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation
  24. (2011). Gronemeyer H: Towards novel paradigms for cancer therapy. Oncogene
  25. (2008). H: TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development.
  26. (2009). He X: Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell
  27. (2003). I: TRAIL induced survival and proliferation in cancer cells resistant towards TRAILinduced apoptosis mediated by NF-kappaB. Oncogene
  28. (1999). JA: 12-Otetradecanoylphorbol-13-acetate induces clonal expansion of potentially malignant keratinocytes in a tissue model of early neoplastic progression. Cancer Res
  29. (2004). KC: Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell
  30. (2001). KC: TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood
  31. (2008). Klein-Szanto AJ, El-Deiry WS: TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis.
  32. (2004). Kraft AS: Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosisinducing ligand-induced apoptosis. Cancer Res
  33. (2002). MJ: Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice.
  34. (2004). MJ: Induction of tumorspecific T cell immunity by anti-DR5 antibody therapy. J Exp Med
  35. (2008). MJ: The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer
  36. (2008). Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr Cancer Drug Targets
  37. (2005). Multistep skin cancer in mice as a model to study the evolution of cancer cells. Semin Cancer Biol
  38. (2010). Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity. Cancer Res
  39. (2001). Okumura K: Involvement of tumor necrosis factor-related apoptosisinducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol
  40. Okumura K: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.
  41. (2010). Pan W: GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem Sci
  42. (2005). Pintzas A: Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway.
  43. (2002). Repasky EA: Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients’ colon tumors grown in SCID mice. Cancer Res
  44. (2008). SG: Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/ Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/ TRAIL).
  45. (2005). Spiegelman VS: Activation of Wnt/beta-catenin/Tcf signaling in mouse skin carcinogenesis. Mol Carcinog
  46. (2002). Targeting death and decoy receptors of the tumournecrosis factor superfamily. Nat Rev Cancer
  47. (2009). The pleiotropic effect of TRAIL on tumor-like synovial fibroblasts from rheumatoid arthritis patients is mediated by caspases. Cell Death Differ
  48. (2007). TM: The promise of TRAIL–potential and risks of a novel anticancer therapy.
  49. (1993). Yuspa SH: The suprabasal expression of alpha 6 beta 4 integrin is associated with a high risk for malignant progression in mouse skin carcinogenesis. Cancer Res
  50. (2008). Zangemeister-Wittke U: TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. Lung Cancer